Intech Investment Management LLC Takes $219,000 Position in Immunome, Inc. (NASDAQ:IMNM)

Intech Investment Management LLC bought a new position in shares of Immunome, Inc. (NASDAQ:IMNM) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,987 shares of the company’s stock, valued at approximately $219,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. California State Teachers Retirement System purchased a new stake in Immunome during the 1st quarter worth approximately $807,000. Cetera Investment Advisers acquired a new stake in Immunome in the first quarter valued at $3,038,000. SG Americas Securities LLC acquired a new position in Immunome during the 2nd quarter worth $1,095,000. Sequoia Financial Advisors LLC bought a new stake in shares of Immunome in the 2nd quarter worth about $206,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Immunome by 279.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 41,570 shares of the company’s stock valued at $503,000 after purchasing an additional 30,617 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Max Rosett sold 14,380 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. This trade represents a 23.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Robert Lechleider purchased 15,805 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was bought at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the acquisition, the insider now directly owns 15,805 shares of the company’s stock, valued at $149,831.40. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 102,862 shares of company stock worth $978,045. 8.60% of the stock is owned by company insiders.

Immunome Trading Up 8.1 %

IMNM opened at $13.73 on Friday. Immunome, Inc. has a twelve month low of $6.93 and a twelve month high of $30.96. The stock has a market cap of $856.99 million, a PE ratio of -1.57 and a beta of 1.83. The business’s 50 day moving average is $12.24 and its 200-day moving average is $13.48.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on IMNM shares. Stephens assumed coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Finally, Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has a consensus rating of “Buy” and a consensus price target of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.